Document is current
Any future updates will be listed below
-
Authors
Ta, Allison D. https://orcid.org/0000-0002-3403-5629
Dillman, Jonathan R.
Ollberding, Nicholas J.
Haberman, Yael
Baldassano, Robert
Markowitz, James
Otley, Anthony
Dotson, Jennifer L.
Pfefferkorn, Marian
Hyams, Jeffrey S.
Heyman, Melvin B.
Kim, Sandra C.
Noe, Joshua
Snapper, Scott
Alazraki, Adina
Kugathasan, Subra
Denson, Lee A.
-
Funding
Funding for this research was provided by:
Crohn's and Colitis Foundation of America (1P30DK078392-01)
Crohn's and Colitis Foundation of America (1P30DK078392-01)
Crohn's and Colitis Foundation of America (1P30DK078392-01)
National Institute of Diabetes and Digestive and Kidney Diseases (DK007727)
- License Information
-
More Information
Article History
Received: 17 May 2024
Revised: 21 May 2025
Accepted: 2 June 2025
First Online: 3 July 2025
Declarations
:
: The institutional review board at each site reviewed the protocol and it was approved. Appropriate written informed consent was obtained in all cases from parents/guardians or patients, and informed assent was provided as appropriate.
: JRD: GE HealthCare, Motilent, Philips Healthcare.JH: Advisory Board Janssen, Abbvie, Lilly, Pfizer, Bristol Myers Squibb. Consultant Takeda.SS: Scientific advisory board participation for Pfizer, Pandion, Celgene, Lilly, Takeda, Cosmo Pharmaceuticals, Merck, Sonoma Biotherapeutics, and EcoR1. Grant support from Pfizer, Amgen Takeda, and Novartis. Consulting for Amgen, Kyverna, BMS, Merck, Third Rock, 89bio, GentiBio, and Apple Tree Life Sciences.
